SHOPIFY INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that SHOPIFY INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.56B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $8.88B | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $7.06B | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $5.60B | Feb 11, 2025 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.56B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $4.47B | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $3.52B | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $2.75B | Feb 11, 2025 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.23B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $2.02B | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $132.00M | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | ($3.46B) | Feb 11, 2025 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.47B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $1.08B | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | ($1.42B) | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | ($822.00M) | Feb 11, 2025 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.54B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $1.37B | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $1.73B | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $1.50B | Feb 11, 2025 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.03B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $1.62B | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $944.00M | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | ($136.00M) | Feb 11, 2025 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $26.00M | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $19.00M | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $39.00M | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $50.00M | Feb 11, 2025 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.19B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $13.92B | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | $11.30B | Feb 11, 2025 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.47B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $11.56B | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $9.07B | Feb 11, 2026 |
| FY2025 | Dec 31, 2022 | $8.24B | Feb 11, 2026 |
| FY2024 | Dec 31, 2021 | $11.13B | Feb 11, 2025 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $491.00M | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $452.00M | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $427.00M | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $1.84B | Feb 11, 2025 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.86B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $1.63B | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | ($390.00M) | Feb 11, 2025 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.55B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $1.50B | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | $1.41B | Feb 11, 2025 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | (2) | Feb 11, 2025 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | (2) | Feb 11, 2025 |